Implantica gears up for FDA approval of acid reflux device
Implantica has started the premarket approval process with the US Food and Drug Administration (FDA) for its gastroesophageal reflux disease…
Implantica has started the premarket approval process with the US Food and Drug Administration (FDA) for its gastroesophageal reflux disease…
Netherland-based Polpharma Biologics has released topline results from a pharmacokinetic (PK) and pharmacodynamic (PD) study of its biosimilar candidate PB016,…
French biopharmaceutical company, Inventiva has paused recruitment for its pivotal Phase III trial for lanifibranor after a trial participant reported…
Hong Kong-based Insilico Medicine has launched a Phase I trial of its artificial intelligence (AI)-discovered drug ISM5411. The Phase I…
This week on Pipeline Moves, we kick off by looking at Phase III trial terminations by Bayer and Johnson &…
Sosei Group Corporation has initiated discussions to regain full ownership of the oral inflammatory bowel disease (IBD) drug GSK4381406 from…
InDex Pharmaceuticals has announced the termination of a Phase III trial of its candidate cobitolimod in patients with ulcerative colitis…
Chimeric Therapeutics has announced plans to commence a Phase IA/B clinical trial of CHM 2101 to treat gastrointestinal cancers. The…
Biora Therapeutics has submitted an updated investigational new drug (IND) application with the US Food and Drug Administration (FDA) for…
US-based biopharmaceutical company Phanes Therapeutics has signed a clinical collaboration agreement with Merck, known as MSD outside North America, to…